Pathway Genomics donates money and fifty BRCA1 and BRCA2 breast cancer tests at no charge for patients at high risk
Pathway Genomics and Susan G. Komen, the largest source of nonprofit funds dedicated to the fight against breast cancer, have announced a partnership to educate women about the screening options available to detect a predisposition to breast cancer. In addition to cash donations Pathway Genomics will provide genetic testing to women in need at no charge. The BRCA1 and BRCA2 genes are a component of Pathway Genomics’ comprehensive Hereditary Cancer DNA InsightSM product, currently scheduled for release in August.
Prior to the recent Supreme Court ruling that invalidated certain patent claims covering BRCA1 and BRCA2 genes, testing for risk of breast and ovarian cancers has been unaffordable for many with tests costing as much as $7000. Pathway Genomics’ test will be more accessible and affordable to patients who are at high risk for breast cancer.
Pathway Genomics announces it will begin offering a BRCA test for breast cancer at a price substantially below the competition
SAN DIEGO (JUNE 14) – Pathway Genomics led the evening news Friday with an announcement that it could begin offering affordable access to genetic testing for the BRCA gene linked to breast and ovarian cancers in the wake of a Supreme Court ruling that eliminated another company’s monopoly on the test.
“These tests, these lifesaving tests will be much more affordable for all of us regardless of how much money is in your pocket.”, Laura Farmer Sherman from the Susan G. Komen chapter told NBC San Diego.
Pathway Genomics, a genetic testing laboratory on the forefront of bringing physicians a broad genetic testing portfolio covering a wide range of diseases, announces the pending launch of its inherited cancer panel with BRCA1 and BRCA2.
Pathway Genomics’ Hereditary Cancer DNA InsightSM test utilizes next-generation sequencing (NGS) technology and will analyze genes related to a selection of hereditary cancers including breast, ovarian, colorectal and others. The company notes that it intends to introduce all their cancer panels in August 2013.
“I am delighted to see laboratories like Pathway offering genetic tests for inherited cancers,” said Linda Wasserman, M.D., Ph.D., former Director of the Clinical Cancer Genetics Care Unit at Moores UCSD Cancer Center. “Next-generation sequencing is a critical step in making actionable genetic information more accessible to the physician, ultimately benefitting the patient.”
Pathway Genomics has partnered with Practice Fusion, the nation’s fastest growing electronic medical record (EMR) community. The partnership will allow Pathway Genomics to rapidly connect and offer its clinical laboratory services to Practice Fusion’s growing network of more than 150,000 medical professionals.
Founded in 2005, Practice Fusion addresses the complexities and critical needs of today’s healthcare environment by providing a free, web-based EMR application to physicians. Through its lab integration solution, practices can receive their patients’ most vital information directly to individual patient charts.
“Our mission, and medical responsibility to the community, is to provide people with actionable and accurate genetic information they can use to maintain health and wellness,” said Dr. Michael Nova, Pathway Genomics’ chief medical officer. “Integrating our lab services into Practice Fusion’s EMR platform is a critical step in making this actionable genetic information more accessible to the physician, and ultimately, the patient.”
Pathway Genomics can now provide genetic testing services to physicians participating in Blue Shield of California’s Preferred Provider Network. With 3.3 million members, Blue Shield of California has an HMO network of more than 34,000 physicians and 290 hospitals, and a PPO network that includes more than 60,000 physicians and 351 hospitals.
Pathway Genomics Corporation, a San Diego-based clinical laboratory that offers genetic testing services internationally, today announced it has appointed Todd G. Johnson, MBA, as vice president of sales and marketing. Based at Pathway Genomics’ San Diego headquarters, in this executive management position, Johnson will assume responsibility for leading the company’s domestic sales division, as well as its marketing and client services teams.
“Todd has a wealth of experience in diagnostics and CLIA laboratories, and has managed sales teams of more than 100 individuals at world-class companies,” said Jim Plante, Pathway Genomics’ founder and CEO.
With more than 60 physicians and specialists, Medcan can now provide Pathway Genomics’ personalized genetic testing services in conjunction with in-person counseling by a certified genetic counselor. The testing service is called The Personal Genome Test and is available to all Medcan patients.
Pathway Genomics participated this week in a panel at the American Society of Human Genetics (ASHG) 2012 Annual Meeting in San Francisco. The panel was focused on issues associated with perceptions of genetic testing, specifically when offered directly to the consumer.
Though Pathway’s genetic testing services are provided exclusively through physicians, the company participated due to its interest in advancing the field of genetic testing. “Concerns over genetic testing are often disproportionate to the reality,” Tanya Moreno, Ph.D., director of research and development at Pathway Genomics, said in Thursday’s panel.
Pathway Genomics has partnered with Scripps Center for Executive Health. The partnership complements Scripps Center for Executive Health, allowing it to offer elements of Pathway Genomics’ extensive suite of genetic tests to patients through Scripps Health physicians, clinics, hospitals and other health care organizations.